These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 26282229

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C, Tebe C, Martinez-Laguna D, Ali MS, Soria-Castro A, Carbonell C, Prieto-Alhambra D.
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
    Borek DM, Smith RC, Gruber CN, Gruber BL.
    Osteoporos Int; 2019 Jul; 30(7):1455-1464. PubMed ID: 31011760
    [Abstract] [Full Text] [Related]

  • 6. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T, Boyanov M, Shinkov A, Petkova R, Intorcia M, Psachoulia E.
    Arch Osteoporos; 2017 Dec 21; 13(1):1. PubMed ID: 29264666
    [Abstract] [Full Text] [Related]

  • 7. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS.
    J Manag Care Spec Pharm; 2015 Sep 21; 21(9):824-33, 833a. PubMed ID: 26308229
    [Abstract] [Full Text] [Related]

  • 8. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, Geusens P, Makras P, Boschitsch E, Callens J, Anastasilakis AD, Niedhart C, Resch H, Kalouche-Khalil L, Hadji P.
    Arch Osteoporos; 2017 Dec 21; 12(1):58. PubMed ID: 28643265
    [Abstract] [Full Text] [Related]

  • 9. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R.
    Arch Osteoporos; 2017 Dec 21; 12(1):22. PubMed ID: 28243883
    [Abstract] [Full Text] [Related]

  • 10. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S, Agodoa I, Bonnick S, Van den Bergh JP, Ferreira I, Ho PR, Brown JP.
    J Clin Endocrinol Metab; 2015 Mar 21; 100(3):E487-92. PubMed ID: 25514106
    [Abstract] [Full Text] [Related]

  • 11. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study.
    Tremblay É, Perreault S, Dorais M.
    Arch Osteoporos; 2016 Dec 21; 11(1):30. PubMed ID: 27679503
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis.
    Yang J, Guo X, Cui Z, Guo H, Dong JN.
    Front Endocrinol (Lausanne); 2024 Dec 21; 15():1431676. PubMed ID: 39286276
    [Abstract] [Full Text] [Related]

  • 14. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.
    Fatoye F, Smith P, Gebrye T, Yeowell G.
    BMJ Open; 2019 Apr 14; 9(4):e027049. PubMed ID: 30987990
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T.
    Osteoporos Int; 2012 Jan 14; 23(1):223-31. PubMed ID: 21308365
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
    Clemens KK, Jeyakumar N, Ouédraogo AM, Thain J, Khan T.
    Arch Osteoporos; 2020 Aug 20; 15(1):133. PubMed ID: 32816151
    [Abstract] [Full Text] [Related]

  • 20. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A.
    Osteoporos Int; 2014 Jan 20; 25(1):339-47. PubMed ID: 24091594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.